SCHEMBL21883076

SCHEMBL21883076

CN(c1ccc2c(c1)c1ccccc1n2C)c1cc(C#N)nc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48
TUBA4A P68366 1/20 0.48
TUBB4B P68371 1/20 0.48
TUBB3 Q13509 1/20 0.48
TUBB2A Q13885 1/20 0.48
TUBB8 Q3ZCM7 1/20 0.48
TUBA3E Q6PEY2 1/20 0.48
TUBA1A Q71U36 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
TUBA1C Q9BQE3 1/20 0.48
TUBB6 Q9BUF5 1/20 0.48
TUBB2B Q9BVA1 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
TUBB1 Q9H4B7 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
MAPT P10636 4/20 0.41
HPGD P15428 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30060707 1.00 TUBB4A (0.48) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL21883075 0.84 MAPT (0.43) MAPTHPGDLMNATSHRALOX15
SCHEMBL23037505 0.83 MAPT (0.48) MAPTHPGDLMNATSHRALOX15
SCHEMBL23037573 0.83 TUBB4A (0.47) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL30062700 0.81 KIF11 (0.41) MAPTHPGDLMNATSHRALOX15
SCHEMBL23668707 0.81 KIF11 (0.41) MAPTHPGDLMNATSHRALOX15
SCHEMBL23668713 0.78 CHKA (0.46) MAPTHPGDLMNATSHRALOX15
SCHEMBL30060686 0.78 CHKA (0.46) MAPTHPGDLMNATSHRALOX15
SCHEMBL25992599 0.78 MEN1 (0.46) MAPTHPGDLMNATSHRALOX15
SCHEMBL23037539 0.77 NCF1 (0.43) MAPTHPGDLMNATSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371417-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties Universite Paris-Saclay (FR) 2025-07-29 US disclosed
US-20230203005-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2023-06-29 US disclosed
US-20230203005-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2023-06-29 US disclosed
US-20230203005-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2023-06-29 US disclosed
EP-3853208-B1 DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES CENTRE NAT RECH SCIENT (FR) 2023-06-07 EP disclosed
US-11634405-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE (FR) 2023-04-25 US disclosed
US-11634405-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE (FR) 2023-04-25 US disclosed
US-20220023435-A1 DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES Universite Paris-Saclay (FR) 2022-01-27 US disclosed
US-20210230140-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2021-07-29 US disclosed
US-20210230140-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2021-07-29 US disclosed
EP-3784662-A1 COMPOUNDS HAVING A TUBULIN-POLYMERISATION-INHIBITING ACTIVITY AND IMMUNOMODULATORY PROPERTIES Université Paris-Saclay (FR) 2021-03-03 EP disclosed
WO-2020058290-A1 DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371417-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties TUBB1, TUBB, TUBB3 TUBB4A 10/4885TUBB 2/4885TUBA3C 15/4885
US-11634405-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties TUBB1, TUBB, TUBB3 TUBB4A 10/4885TUBB 2/4885TUBA3C 15/4885
US-20230203005-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES TUBB1, TUBB, TUBB3 TUBB4A 10/4885TUBB 2/4885TUBA3C 15/4885
US-20220023435-A1 DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES HRH3, ABCC3, ORC3 TUBB4A 1383/4885TUBB 739/4885TUBA3C 147/4885
US-20210230140-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES TUBB1, TUBB, TUBB3 TUBB4A 10/4885TUBB 2/4885TUBA3C 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.